Why Omeros (OMER) Is Up 74.0% After First-In-Class TA-TMA Drug Wins FDA Approval [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
stem cell transplant-associated thrombotic microangiopathy (TA-TMA) in adults and children aged two and older, with a U.S. launch planned for January 2026 and an EMA decision expected mid-2026. This approval not only moves Omeros from a development-stage to a commercial-stage company but also positions YARTEMLEA as a first-mover treatment in a life-threatening, previously untreated condition, potentially reshaping the company's role in complement-mediated disease therapy. With YARTEMLEA's first-in-class TA-TMA approval in hand, we'll examine how this milestone reshapes Omeros' investment narrative. Uncover the next big thing with financially sound penny stocks that balance risk and reward For anyone looking at Omeros today, the core thesis now turns on whether YARTEMLEA can successfully carry the company from zero revenue and recurring losses into a sustainable commercial footing. The FDA approval is clearly a major catalyst: it removes the regulatory overhang around narsoplim
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Health care will get more expensive for some in 2026 — and cheaper for others [MSNBC.com]MSNBC.com
- Novo Nordisk (CPSE:NOVO B) Is Up 9.0% After FDA Clears First Oral Wegovy Pill [Yahoo! Finance]Yahoo! Finance
- U.S. regulators approve Wegovy pill for weight loss [Los Angeles Times (CA)]Los Angeles Times
- Novo, Lilly race to cement lead in India's obesity drug market, Reuters says [Yahoo! Finance]Yahoo! Finance
- Health care will get more expensive for some in 2026 – and cheaper for others [MSNBC.com]MSNBC.com
NVO
Earnings
- 11/6/25 - Beat
NVO
Sec Filings
- 12/23/25 - Form 6-K
- 11/25/25 - Form 6-K
- 11/24/25 - Form 6-K
- NVO's page on the SEC website